Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers

NCT: NCT07758855 · COMPLETED

NCT IDNCT07758855
StatusCOMPLETED
Start Date2024-05-06
Completion2026-08-05
SponsorAnkara City Hospital Bilkent (OTHER)
First posted
Last updated

Brief Summary

Diabetic foot ulcers are the complication of diabetes most frequently requiring hospitalization and carry very high treatment costs. Ulcers that fail to heal may lead to amputation of the foot or leg, causing permanent disability and major loss of working capacity. Neuropathy, vasculopathy and infection are the principal drivers of ulcer formation, and the bacteria encountered in these ulcers frequently show high antibiotic resistance. Locally acting wound care products are therefore of considerable importance. Silver has been used in wound treatment since antiquity. Silver nanoparticles have broad antibacterial, antifungal and antiviral properties: they can penetrate bacterial cell walls, alter membrane structure, increase membrane permeability, generate reactive oxygen species and release silver ions that inhibit deoxyribonucleic acid replication, and may result in cell death. Nanotechnologically produced silver products are thought to achieve greater tissue penetration and anti-infective activity, which is also relevant to the biofilm layer formed by bacteria, a recognised barrier to healing that is highly resistant to conventional antimicrobial therapy. This study evaluates the effects of a nanotechnologically produced, Turkish-manufactured silver-coated wound care dressing in diabetic foot ulcers, compared with conventional dressing using sterile saline-moistened gauze. Participants with a PEDIS grade 2 or grade 3 diabetic foot ulcer are allocated to the investigational dressing or to the conventional dressing. All participants receive routine diabetic foot care in addition to the assigned dressing. Wounds are assessed on days 0, 3, 7 and 21 by wound measurement, deep tissue culture and histopathological examination of tissue obtained at debridement.

Frequently Asked Questions

What is Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers?

Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers is a clinical trial registered under NCT07758855. Current status: COMPLETED.

What is the status of NCT07758855?

The current status of NCT07758855 (Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers) is: COMPLETED.

When did Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers start?

Nanotechnological Silver-Coated Dressing in Diabetic Foot Ulcers started on 2024-05-06.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.